SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction inj… Read more
SanBio Company Limited - Asset Resilience Ratio
SanBio Company Limited (SNBIF) has an Asset Resilience Ratio of 0.00% as of July 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2019)
This chart shows how SanBio Company Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down SanBio Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: SanBio Company Limited maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
SanBio Company Limited Industry Peers by Asset Resilience Ratio
Compare SanBio Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for SanBio Company Limited (2016–2019)
The table below shows the annual Asset Resilience Ratio data for SanBio Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-01-31 | 0.00% | $0.00 | $13.98 Billion | -- |
| 2018-01-31 | 0.00% | $0.00 | $5.19 Billion | -- |
| 2017-01-31 | 0.00% | $0.00 | $6.29 Billion | -- |
| 2016-01-31 | 0.00% | $0.00 | $8.27 Billion | -- |